Form 8-K - Current report:
SEC Accession No. 0001140361-25-023261
Filing Date
2025-06-23
Accepted
2025-06-23 08:00:43
Documents
14
Period of Report
2025-06-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20050698_8k.htm   iXBRL 8-K 33121
2 EXHIBIT 99.1 ef20050698_ex99-1.htm EX-99.1 142064
6 image00001.jpg GRAPHIC 3564
  Complete submission text file 0001140361-25-023261.txt   324953

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA grce-20250623.xsd EX-101.SCH 3859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE grce-20250623_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grce-20250623_pre.xml EX-101.PRE 16040
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20050698_8k_htm.xml XML 4214
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Grace Therapeutics, Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 251062992
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)